Estimates of the lifetime costs of breast cancer treatment in Canada.
about
First do no harm: extending the debate on the provision of preventive tamoxifenThe role of private care in the interval between diagnosis and treatment of breast cancer in Northern Ireland: an analysis of Registry data.Introduction of a breast cancer care programme including ultra short hospital stay in 4 early adopter centres: framework for an implementation studyCost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerA comparative analysis of monthly out-of-pocket costs for patients with breast cancer as compared with other common cancers in Ontario, Canada.Health system costs for stage-specific breast cancer: a population-based approach.A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in CanadaThe cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.The Population Health Model (POHEM): an overview of rationale, methods and applicationsA Micro CT Study in Patients with Breast Microcalcifications Using a Mathematical Algorithm to Assess 3D Structure.The Economic Burden of Breast Cancer in Iran.Cost of treatment for breast cancer in central Vietnam.Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada.Total cost-effectiveness of mammography screening strategiesThe economic burden of cancers attributable to tobacco smoking, excess weight, alcohol use, and physical inactivity in Canada.Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.Overview of methods to estimate the medical costs of cancerCost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer.Health care costs associated with hepatocellular carcinoma: a population-based study.Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.A microsimulation cost-utility analysis of alcohol screening and brief intervention to reduce heavy alcohol consumption in Canada.Factors Affecting the Postsurgical Length of Hospital Stay in Patients with Breast Cancer.Investigating the complementary value of discrete choice experiments for the evaluation of barriers and facilitators in implementation research: a questionnaire survey.Lifetime costs of the top five cancers in Taiwan.Rational choice(s)? Rethinking decision-making on breast cancer risk and screening mammography.Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?Wage losses in the year after breast cancer: extent and determinants among Canadian women.Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.Economic burden of colorectal cancer in Iran in 2012.Screening for breast cancer in 2018-what should we be doing today?CANADIAN CANCER RISK MANAGEMENT MODEL: EVALUATION OF CANCER CONTROLThe evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model
P2860
Q28365007-2BA626B4-C0E5-453A-AF1E-423FA4371A48Q30707238-24679DAC-CDC6-4A42-BA42-7C7B3BF94C72Q33289661-1F91BE48-7F01-4EF0-9BBF-A0A490C069C9Q33680393-54296D7D-E75C-47DE-BECF-7CF4EF325009Q33909250-C0636F88-407B-4439-BE99-107659EBA76AQ34022200-9AD8D2D0-2F7A-4BBB-8B15-EA0932B7012AQ34541453-81904A68-FF72-478F-921B-C9D48F1B80C4Q34637835-FECFA0C8-3A25-47AA-81BB-C4E7E9CDF76CQ34761601-6E59EDB2-9E9D-4E83-ADD1-F4FF6C71CD70Q35445037-8ED4E058-441D-4941-A75C-2BD99E73A638Q35573019-3799C38D-5044-45AC-8C89-135DBCFB6A86Q35934290-52660612-186B-49E3-B3AF-5182FEFB4E7BQ36025063-C684B076-F70B-4109-9C70-4D6EA687CA27Q36255661-E23D70C7-A39A-4DE5-AF5C-313B1D0CA653Q36282180-A607E909-F76F-49C6-A0A5-5F03F61387D6Q36588924-011A63A3-359D-4F15-80EA-2DEA18EE7662Q36611011-092C9E8B-5277-437B-AA2D-199B0B44E800Q36742558-0F878818-38A5-4E26-AF9D-C569284C73CBQ36972762-A2793D09-F0B4-419C-BA92-5C1FF1DD6A9EQ37152885-D16CBE6A-13DB-4F66-9799-2B8D6BA8F0C2Q37247986-765C0E0B-06E7-4458-AE72-5EE25B15DFF3Q37286387-43A69599-C018-4FAD-9476-3A2B7B9EAD76Q37763149-0308832F-C8C2-4AE7-910F-DD283F48E331Q39489363-E008ACB8-D845-40D0-AABD-7056C89EFCDFQ40420167-E4F1069B-DBD4-4C96-A95D-6B34BBD4412AQ40442265-3E382A54-D06E-43BD-ABA0-22D678513B7DQ40951867-9815E81C-6798-4D95-A07A-21EBDC476834Q41205797-9F422381-33A2-4963-922B-B17784FF6351Q42316321-E944318F-256C-47B0-9F19-7DEFB6A6AA83Q43164732-EE0D684C-5836-4A41-A7E0-32CB96BA4B2FQ46635786-7FF2780C-EAE2-4903-9634-F155C9530482Q47380432-72FACD6B-370C-45F3-B7D5-BD41212F0B1DQ48171553-D913ACEC-19E4-49DA-AFDC-F73660EE8F4CQ51114313-E956D426-562D-4B01-8E2A-D4240E993DE9Q53386515-C1667598-1740-485C-8637-5EA7A9636DE7Q55286396-F4AB983B-E00C-42B9-9193-985412D202F4Q55396634-C7A67394-F02E-4B1A-A736-912D98CD8384Q58287522-1A66D99D-6436-4E98-8532-FAFDE3AEBE2EQ58287526-0F39936D-7AE0-44FD-A9E8-87F34E9A22DB
P2860
Estimates of the lifetime costs of breast cancer treatment in Canada.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Estimates of the lifetime costs of breast cancer treatment in Canada.
@en
Estimates of the lifetime costs of breast cancer treatment in Canada.
@nl
type
label
Estimates of the lifetime costs of breast cancer treatment in Canada.
@en
Estimates of the lifetime costs of breast cancer treatment in Canada.
@nl
prefLabel
Estimates of the lifetime costs of breast cancer treatment in Canada.
@en
Estimates of the lifetime costs of breast cancer treatment in Canada.
@nl
P2093
P1476
Estimates of the lifetime costs of breast cancer treatment in Canada.
@en
P2093
P304
P356
10.1016/S0959-8049(99)00340-8
P577
2000-04-01T00:00:00Z